TransMedics Group (NASDAQ:TMDX) Price Target Raised to $175.00

TransMedics Group (NASDAQ:TMDX) had its price objective increased by Oppenheimer from $150.00 to $175.00 in a research report report published on Wednesday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

A number of other research analysts also recently weighed in on the company. Wall Street Zen raised TransMedics Group from a “hold” rating to a “buy” rating in a research note on Saturday, February 14th. Morgan Stanley upped their target price on TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. JPMorgan Chase & Co. increased their target price on TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a report on Wednesday. Canaccord Genuity Group boosted their price target on shares of TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Finally, Piper Sandler upped their price objective on shares of TransMedics Group from $140.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday. Six research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, TransMedics Group presently has a consensus rating of “Moderate Buy” and an average price target of $150.67.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $145.26 on Wednesday. The firm has a market capitalization of $4.98 billion, a P/E ratio of 29.64 and a beta of 2.06. The firm’s 50-day moving average price is $133.80 and its 200-day moving average price is $126.44. The company has a current ratio of 7.14, a quick ratio of 7.13 and a debt-to-equity ratio of 1.06. TransMedics Group has a 1-year low of $62.07 and a 1-year high of $156.00.

Insider Buying and Selling at TransMedics Group

In related news, Director David Weill sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total transaction of $693,200.00. Following the transaction, the director directly owned 12,134 shares of the company’s stock, valued at $1,682,257.76. This trade represents a 29.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Gerardo Hernandez sold 920 shares of the company’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $139.62, for a total transaction of $128,450.40. Following the completion of the sale, the chief financial officer directly owned 15,064 shares of the company’s stock, valued at $2,103,235.68. The trade was a 5.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 7.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds and other institutional investors have recently modified their holdings of TMDX. Whittier Trust Co. of Nevada Inc. grew its holdings in shares of TransMedics Group by 981.0% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock valued at $26,000 after acquiring an additional 206 shares in the last quarter. Salomon & Ludwin LLC bought a new stake in TransMedics Group during the third quarter worth $28,000. Harvest Fund Management Co. Ltd purchased a new position in TransMedics Group in the third quarter worth $29,000. Optiver Holding B.V. boosted its position in TransMedics Group by 248.1% in the third quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after purchasing an additional 191 shares during the last quarter. Finally, Allworth Financial LP grew its stake in TransMedics Group by 74.3% in the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after purchasing an additional 113 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.